New stronger weight-loss drug gets green light from FDA: 'Major jump'

This material may not be published, broadcast, rewritten, or redistributed. ©2026 FOX News Network, LLC. All rights reserved. Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions. Legal Statement. Mutual Fund and ETF data provided by LSEG. Board certified rheumatologist Dr. Mahsa Tehrani discusses Novo Nordisk's decision to dramatically cut the U.S. list prices for its popular diabetes and weight-loss drugs Ozempic and Wegovy on ‘America Reports.’ The U.S. Food and Drug Administration announced on Thursday its approval of a new, higher-dose Wegovy (semaglutide) injection. The 7.2 mg dosage, called Wegovy HD, is intended for weight loss and long-term weight loss maintenance for adult patients. It is triple the previous maximum dose of 2.4 mg. This marks the fourth approval in the FDA's National Priority Voucher pilot program, which "seeks to expedite approval of applications that address critical national health priorities," according to FDA Commissioner Dr. Martin Makary. NEW WEGOVY PILL OFFERS NEEDLE-FREE WEIGHT LOSS – BUT MAY NOT WORK FOR EVERYONE "The new FDA is moving with unpreced
Source: For the complete article, please visit the original source link below.





